T2 Biosystems, Inc. (TTOO) said it plans to commercialize the T2Lyme Panel in the third quarter of 2024 as a laboratory developed test without the need to be run on the T2Dx Instrument providing throughput improvements and cost of goods advantages. The company is in talks with potential LDT partners and plans to provide early Lyme disease results to U.S. reference laboratories nationwide.
The company continues to expect 2024 total sepsis and related product revenue of $10.0 million to $11.0 million, representing growth of 49% to 64%, compared to $6.7 million in 2023.
John Sperzel, CEO of T2 Biosystems, said: "We continue to prioritize our Nasdaq listing and advance the review of strategic alternatives which are both intended to increase shareholder value."
Shares of T2 Biosystems are up 14% in pre-market trade on Wednesday.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.